<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="41668">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01656824</url>
  </required_header>
  <id_info>
    <org_study_id>Bv8/PK-2CTIL</org_study_id>
    <nct_id>NCT01656824</nct_id>
  </id_info>
  <brief_title>Tissue Study of Bv8/PK-2 Inhibition in Human Cancer</brief_title>
  <official_title>Study of Human Primary Cancer Tissue Implanted in Mice Lacking Bv8/PH-2 in Their Bone Marrow-derived Cells</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rambam Health Care Campus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rambam Health Care Campus</source>
  <oversight_info>
    <authority>Israel: Ministry of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study hypothesis is that inhibition of Bv8 production in bone marrow cells of a mice wil
      reduce the rate of growth of a primary human tumor implanted in the mice. we will take mice
      and transform their bone marrow cells into non-Bv8 producing cells. than we will implant
      primary human tumor tissue (taken from surgical specimens after informed consent)in those
      mice and follow-up on the mice.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1-10 grams of human cancer tissue will be taken from surgical specimen without interference
      to the pathological data gathering process. those tissues will be implanted in nude mice
      that will either be treated with anti-Bv8 antibodies or will be transplanted with bone
      marrow in which Bv8 expression is silenced.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Anticipated">October 2014</completion_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>N/A</study_design>
  <primary_outcome>
    <measure>Tumor growth in xenograft model</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Cancer</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      cancer tissues
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients diagnosed with pancreatic cancer and are candidates for whipple's procedure
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ages 18-85 years

          -  Pathologically-confirmed diagnosis of pancreatic ductal adenocarcinoma undergoing
             surgical pancreaticoduodenectomy

        Exclusion Criteria:

          -  refuse to take part

          -  preoperative chemotherapy
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Erez Hasnis, MD;PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rambam Health Care Campus</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Erez Hasnis, MD; PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rambam Health Care Campus</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Erez Hasnis, MD; PhD</last_name>
    <phone>972-50-2061911</phone>
    <email>e_hasnis@rambam.health.gov.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>Rambam Medical Center</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erez Hasnis, MD;PhD</last_name>
      <phone>972-50-2061911</phone>
      <email>e_hasnis@rambam.health.gov.il</email>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 20, 2013</lastchanged_date>
  <firstreceived_date>August 1, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bv8/PK-2</keyword>
  <keyword>MDSC Myeloid Derived Suppressor Cells</keyword>
  <keyword>BMDC Bone Marrow Derived Cells</keyword>
  <keyword>Angiogenesis</keyword>
  <keyword>Pancreatic Cancer</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
